




RESEARCH | INVESTMENT ADVISER

Daily Report

20-12-2019



MARKET WRAPUP:




Despite a range-bound trade, domestic markets hit fresh lifetime highs for the third consecutive day on Friday. Investment sentiment remained in check in the absence of any key global and domestic cues. Sensex closed at 41,681.54-level, up 7.62 points or 0.018 percent. On the NSE, the broader Nifty50 settled little changed at 12,271.8-mark, up 12.1 points or 0.09 percent. The benchmark Sensex and Nifty hit fresh highs of 41,809.96 and 12,293.90, respectively. On the sectoral front, public sector banks gained the most on Friday after the Reserve Bank of India (RBI) decided to buy and sell bonds worth Rs 10,000 crore via open market operations. At close, the Nifty PSU bank index was the top performer on the NSE, up over 2 percent. On the downside, Nifty Auto index slipped 0.45 percent. TITAN, TATASTEEL, UPL are the top gainers while the VEDL, KOTAKBANK, TATAMOTORS are the top losers of the day.


NIFTY PIVOTS

SCRIPT	R1	R2	R3	PIVOT	S1	S2	S3
NIFTY	12305	12322	12364	12280	12263	12238	12196


INDEX HEAT MAP:



Fund Flow Activities In Last 5 Sessions



Global Equity Market Performance:



STOCK IN NEWS

Ipca Labs: The company has entered into an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named "Atoguanil".

JB Chemicals: JB Chemicals and Pharmaceuticals said that reports appearing in some sections of the media indicating that their brand Rantac (Ranitidine molecule) has been banned, is false and incorrect. The company would like to categorically assert that their product Rantac is not banned by the regulatory authorities. As a responsible manufacturer, company continues to manufacture Rantac which complies with all the standards set by the Drug Controller General of India (DCG(I)).

Cadila Healthcare: USFDA inspected the company's topical manufacturing facility located in Ahmedabad from 16 to 20 December, 2019. At the end of the inspection, no observation (483) is issued.

Lupin: The company has received approval for its Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. The product will be manufactured at Lupin's Pithampur (Unit 3) facility, India.

Ratnamani: The company has received two major orders in carbon steel division including domestic order of Rs 124 crore for supply of coated CS pipes for an oil & gas pipeline project to be completed between April to September, 2020 and export order of USD 14.30 million (equivalent to approx Rs100 crore) for supply of bare CS Pipes to be completed between May to June, 2020.

DBL: Nidagatta Mysore Highways Private Limited, wholly owned subsidiary of Dilip Buildcon has received the appointed date i.e. December 10, 2019 by the National Highways Authority of India for Six- Laning from Nidagatta Mysore Section in the State of Karnataka to be executed on Annuity Mode.

Glenmark: Seqirus Pty. Ltd. has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris in Australia through our partner, Seqirus. Australia will be the first market globally where Ryaltris will be launched.

STOCK RECOMMENDATIONS

TODAY:

SCRIPT	ACTION	LEVEL	RESULT
BATA (CASH)	BUY	B-1699T-1710 SL-1686	
COLPAL(FUT)	BUY	B-1493 T-1507 SL-1479	

YESTERDAY:

SCRIPT	ACTION	LEVEL	RESULT
ESCORTS (CASH)	BUY	B-626 T-631 SL-620	DOES TARGET
SIEMENS(FUT)	BUY	B-1544 T-1560 SL-1530	SL TRIGGERED